Do analysts rate SONX or ALUR?

Allurion Technologies has a consensus target price of $3.00, indicating a potential upside of 550.62%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Allurion Technologies is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer ICU or SONX?

SeaStar Medical presently has a consensus price target of $8.00, indicating a potential upside of 157.23%. Given SeaStar Medical's stronger consensus rating and higher probable upside, equities research analysts plainly believe SeaStar Medical is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ICU or SONX more profitable?

Sonendo has a net margin of -92.74% compared to SeaStar Medical's net margin of -828.62%. SeaStar Medical's return on equity of -146.29% beat Sonendo's return on equity. Company Net Margins Return on Equity Return on Assets SeaStar Medical -828.62% -146.29% -96.48% Sonendo -92.74% -184.01% -68.60%

Do analysts rate SONX or QNRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer SONX or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SONX or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Check-Cap's return on equity of 0.00% beat Sonendo's return on equity. Company Net Margins Return on Equity Return on Assets Sonendo -92.74% -184.01% -68.60% Check-Cap N/A N/A N/A

Do analysts recommend NXL or SONX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NXL or SONX more profitable?

Sonendo has a net margin of -92.74% compared to Nexalin Technology's net margin of -3,018.12%. Sonendo's return on equity of -184.01% beat Nexalin Technology's return on equity. Company Net Margins Return on Equity Return on Assets Nexalin Technology -3,018.12% -191.88% -166.43% Sonendo -92.74% -184.01% -68.60%

Sonendo (SONX) Competitors

$0.60 0.00 (0.00%)

As of 06/12/2026

Compare

SONX vs. ALUR, ICU, QNRX, MBAI, and NXL

Should you buy Sonendo stock or one of its competitors? MarketBeat compares Sonendo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sonendo include Allurion Technologies (ALUR), SeaStar Medical (ICU), Quoin Pharmaceuticals (QNRX), Check-Cap (MBAI), and Nexalin Technology (NXL). These companies are all part of the "medical equipment" industry.

How does Sonendo compare to Allurion Technologies?

Sonendo (NYSE:SONX) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Allurion Technologies has a consensus target price of $3.00, indicating a potential upside of 550.62%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Allurion Technologies is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

28.7% of Sonendo shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 7.9% of Sonendo shares are owned by insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Sonendo's average media sentiment score of 0.00 equaled Allurion Technologies'average media sentiment score.

Company	Overall Sentiment
Sonendo	Neutral
Allurion Technologies	Neutral

Sonendo has a net margin of -92.74% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
Allurion Technologies	-199.96%	N/A	-77.13%

Sonendo has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

Allurion Technologies has lower revenue, but higher earnings than Sonendo. Allurion Technologies is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A
Allurion Technologies	$17.21M	0.40	-$7.20M	-$2.03	N/A

Summary

Allurion Technologies beats Sonendo on 8 of the 14 factors compared between the two stocks.

How does Sonendo compare to SeaStar Medical?

SeaStar Medical (NASDAQ:ICU) and Sonendo (NYSE:SONX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

SeaStar Medical presently has a consensus price target of $8.00, indicating a potential upside of 157.23%. Given SeaStar Medical's stronger consensus rating and higher probable upside, equities research analysts plainly believe SeaStar Medical is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

SeaStar Medical has higher earnings, but lower revenue than Sonendo. SeaStar Medical is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SeaStar Medical	$1.44M	8.66	-$12.15M	-$4.80	N/A
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A

1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 28.7% of Sonendo shares are owned by institutional investors. 0.7% of SeaStar Medical shares are owned by company insiders. Comparatively, 7.9% of Sonendo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, SeaStar Medical had 2 more articles in the media than Sonendo. MarketBeat recorded 2 mentions for SeaStar Medical and 0 mentions for Sonendo. SeaStar Medical's average media sentiment score of 1.59 beat Sonendo's score of 0.00 indicating that SeaStar Medical is being referred to more favorably in the media.

Company	Overall Sentiment
SeaStar Medical	Very Positive
Sonendo	Neutral

SeaStar Medical has a beta of -1.05, suggesting that its stock price is 205% less volatile than the broader market. Comparatively, Sonendo has a beta of 2.01, suggesting that its stock price is 101% more volatile than the broader market.

Sonendo has a net margin of -92.74% compared to SeaStar Medical's net margin of -828.62%. SeaStar Medical's return on equity of -146.29% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SeaStar Medical	-828.62%	-146.29%	-96.48%
Sonendo	-92.74%	-184.01%	-68.60%

Summary

SeaStar Medical beats Sonendo on 9 of the 16 factors compared between the two stocks.

How does Sonendo compare to Quoin Pharmaceuticals?

Sonendo (NYSE:SONX) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Sonendo has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Sonendo. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 0 mentions for Sonendo. Quoin Pharmaceuticals' average media sentiment score of 1.43 beat Sonendo's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonendo	Neutral
Quoin Pharmaceuticals	Positive

Quoin Pharmaceuticals has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

28.7% of Sonendo shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 7.9% of Sonendo shares are held by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quoin Pharmaceuticals has lower revenue, but higher earnings than Sonendo. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Summary

Quoin Pharmaceuticals beats Sonendo on 8 of the 14 factors compared between the two stocks.

How does Sonendo compare to Check-Cap?

Sonendo (NYSE:SONX) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

28.7% of Sonendo shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 7.9% of Sonendo shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Check-Cap had 3 more articles in the media than Sonendo. MarketBeat recorded 3 mentions for Check-Cap and 0 mentions for Sonendo. Check-Cap's average media sentiment score of 1.21 beat Sonendo's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonendo	Neutral
Check-Cap	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sonendo has a beta of 2.01, suggesting that its stock price is 101% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

Check-Cap has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Check-Cap's return on equity of 0.00% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
Check-Cap	N/A	N/A	N/A

Check-Cap has lower revenue, but higher earnings than Sonendo. Check-Cap is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

Summary

Check-Cap beats Sonendo on 8 of the 13 factors compared between the two stocks.

How does Sonendo compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and Sonendo (NYSE:SONX) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Nexalin Technology has a beta of 3.8, suggesting that its stock price is 280% more volatile than the broader market. Comparatively, Sonendo has a beta of 2.01, suggesting that its stock price is 101% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Nexalin Technology had 5 more articles in the media than Sonendo. MarketBeat recorded 5 mentions for Nexalin Technology and 0 mentions for Sonendo. Nexalin Technology's average media sentiment score of 0.85 beat Sonendo's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Nexalin Technology	Positive
Sonendo	Neutral

Nexalin Technology has higher earnings, but lower revenue than Sonendo. Nexalin Technology is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$275.58K	30.99	-$8.22M	-$0.47	N/A
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A

0.6% of Nexalin Technology shares are owned by institutional investors. Comparatively, 28.7% of Sonendo shares are owned by institutional investors. 25.3% of Nexalin Technology shares are owned by company insiders. Comparatively, 7.9% of Sonendo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sonendo has a net margin of -92.74% compared to Nexalin Technology's net margin of -3,018.12%. Sonendo's return on equity of -184.01% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Sonendo	-92.74%	-184.01%	-68.60%

Summary

Nexalin Technology beats Sonendo on 8 of the 14 factors compared between the two stocks.

Get Sonendo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SONX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SONX vs. The Competition

Export

Metric	Sonendo	Dental equipment & supplies Industry	Medical Sector	NYSE Exchange
Market Cap	$2.87M	$2.87M	$6.48B	$23.42B
Dividend Yield	N/A	N/A	2.67%	4.06%
P/E Ratio	-0.01	N/A	23.95	31.66
Price / Sales	0.06	0.06	536.37	101.28
Price / Cash	N/A	N/A	27.48	18.65
Price / Book	0.01	0.01	10.44	4.71
Net Income	-$60.92M	-$60.92M	$3.56B	$1.08B
7 Day Performance	N/A	N/A	0.83%	2.18%
1 Month Performance	-25.00%	-25.00%	1.78%	3.54%
1 Year Performance	N/A	-47.83%	25.59%	24.66%

Sonendo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SONX Sonendo	N/A	$0.60 flat	N/A	N/A	$2.87M	$44.40M	N/A	250
ALUR Allurion Technologies	1.3438 of 5 stars	$0.71 -10.0%	$3.00 +321.9%	-73.5%	$10.66M	$17.21M	N/A	501	Gap Down
ICU SeaStar Medical	3.1189 of 5 stars	$2.73 +3.8%	$8.00 +193.0%	-74.7%	$10.51M	$1.23M	N/A	2	Positive News Gap Up
QNRX Quoin Pharmaceuticals	1.5765 of 5 stars	$4.70 -7.1%	N/A	-49.9%	$10.16M	N/A	N/A	4	Analyst Forecast Short Interest Decrease Gap Down
MBAI Check-Cap	0.9471 of 5 stars	$1.37 +3.0%	N/A	N/A	$9.69M	N/A	N/A	80	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SONX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonendo (SONX) Competitors

SONX vs. ALUR, ICU, QNRX, MBAI, and NXL

How does Sonendo compare to Allurion Technologies?

Summary

How does Sonendo compare to SeaStar Medical?

Summary

How does Sonendo compare to Quoin Pharmaceuticals?

Summary

How does Sonendo compare to Check-Cap?

Summary

How does Sonendo compare to Nexalin Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SONX vs. The Competition

Sonendo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sonendo (SONX) Competitors

SONX vs. ALUR, ICU, QNRX, MBAI, and NXL

How does Sonendo compare to Allurion Technologies?

Do analysts rate SONX or ALUR?

Do institutionals & insiders have more ownership in SONX or ALUR?

Does the media refer more to SONX or ALUR?

Is SONX or ALUR more profitable?

Which has more risk and volatility, SONX or ALUR?

Which has stronger earnings and valuation, SONX or ALUR?

Summary

How does Sonendo compare to SeaStar Medical?

Do analysts prefer ICU or SONX?

Which has stronger valuation & earnings, ICU or SONX?

Do institutionals and insiders have more ownership in ICU or SONX?

Does the media favor ICU or SONX?

Which has more risk and volatility, ICU or SONX?

Is ICU or SONX more profitable?

Summary

How does Sonendo compare to Quoin Pharmaceuticals?

Which has more risk and volatility, SONX or QNRX?

Does the media refer more to SONX or QNRX?

Is SONX or QNRX more profitable?

Do institutionals & insiders believe in SONX or QNRX?

Do analysts rate SONX or QNRX?

Which has preferable valuation and earnings, SONX or QNRX?

Summary

How does Sonendo compare to Check-Cap?

Do institutionals and insiders believe in SONX or MBAI?

Does the media refer more to SONX or MBAI?

Do analysts prefer SONX or MBAI?

Which has more volatility & risk, SONX or MBAI?

Is SONX or MBAI more profitable?

Which has preferable valuation & earnings, SONX or MBAI?

Summary

How does Sonendo compare to Nexalin Technology?

Which has more risk and volatility, NXL or SONX?

Do analysts recommend NXL or SONX?

Does the media favor NXL or SONX?

Which has higher valuation & earnings, NXL or SONX?

Do insiders & institutionals believe in NXL or SONX?

Is NXL or SONX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SONX vs. The Competition

Sonendo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools